Cardio Diagnostics Holdings

Cardio Diagnostics Holdings

Cardio Diagnostics Holdings was founded in 2017 by Meesha Dogan, an engineer turned entrepreneur, and Dr. Robert Philibert, a physician-scientist whose academic career produced the intellectual property at the firm's core. The company is not a family office, a fund, or an allocation vehicle. It operates as a publicly traded commercial-stage biotechnology company that manufacturers and distributes epigenetic-genetic blood tests. Its headquarters sit in Chicago, with a corporate footprint typical of early-stage public life-science companies. The firm markets two laboratory-developed tests: Epi+Gen CHD, a single blood draw that analyzes DNA methylation and genetic markers to predict a three-year risk for coronary heart disease, and PrecisionCHD, a companion test that assesses a patient's current likelihood of having coronary artery disease. These are not deep-tech biotech moonshots; they are commercial products targeting the gap between a standard cholesterol panel and an invasive angiogram. The commercial strategy leans on telemedicine and point-of-care deployment rather than competing for scarce cardiologist shelf space. In 2023, the company integrated its tests onto the Air Force Research Laboratory’s hypertension digital platform, signaling a pivot toward federal and employer-based contracts. The company is micro-cap, trading on the Nasdaq under the ticker CDIO. It does not manage third-party capital. Its economic engine runs on test-kit revenue and, critically, on selling stock into the public market — a structure shared by many pre-revenue and low-revenue diagnostics companies. In September 2024, Cardio Diagnostics announced a $1.9 million registered direct offering, a common capital-raise cadence for firms of its size. The balance sheet and periodic registered offerings function as the firm's de facto fund structure. The structural differentiator is not the science — dozens of genetic-testing startups promise risk stratification. The architecture's distinction lies in its hybrid go-to-market model: bypassing the specialist-CME-marketing trap by selling directly to self-insured employers and health systems, and embedding its software into existing telemedicine workflows. For any single family office evaluating this as a private investment, the core tension is clear — the asset is an illiquid life-science stock with a narrow cash runway and a share price more tied to financing cadence than to test-card volume.